First DCT Regulatory Science Project Involving MUST Clinical Trial Center Successfully Approved by NMPA Greater Bay Area Branch

Led by the Hong Kong University-Shenzhen Hospital, in collaboration with The Macau University of Science and Technology, University of Hong Kong, and Gleneagles Hospital Hong Kong, the research project on "Decentralized Clinical Trial (DCT) Risk Management and System Development" has been officially approved as a 2025 Regulatory Science Initiative by the NMPA Division of Drug Evaluation and Inspection for the Greater Bay Area.

This project is the first regulatory science research initiative in the Greater Bay Area focused on Decentralized Clinical Trials (DCT). It aims to systematically analyze the key implementation points and potential risks of remote intelligent clinical trials in China, leveraging the unique characteristics and advantages of the Greater Bay Area to establish a scientific DCT risk assessment and management system.